Intravenous and Subcutaneous Administration of Desmopresssin (DDAVP) to Hemophiliacs: Pharmacokinetics and Factor VIII Responses
Intravenous and Subcutaneous Administration of Desmopresssin (DDAVP) to Hemophiliacs: Pharmacokinetics and Factor VIII Responses
复制标题
血友病患者静脉和皮下注射去氨加压素 (DDAVP)：药代动力学和因子 VIII 反应
DOI：
10.1055/s-0038-1646051
复制
发表时间：
1987
影响因子：
6.7
通讯作者：
A. Lindquist
中科院分区：
文献类型：
--
作者：
P. Mannucci;V. Vicente;I. Alberca;E. Sacchi;G. Longo;A. Harris;A. Lindquist
Summary When desmopressin (DDAVP) is given to mild and moderate hemophiliacs intravenously (i. v.) or subcutaneously (s.c.), there is a very large between-patient variability for peak levels of factor VIII coagulant activity (VIII :C). To evaluate whether or not between-patient variability is related to DDAVP levels achieved in plasma, we measured drug levels in 14 hemophilic volunteers (VIII: C 2 to 31 U/dL) who were randomly given 0.3 μg/Kg of i. v. or s. c. DDAVP and crossed-over to the other treatment after an interval of 15–30 days. Peak DDAVP levels (Cmax) were higher for i.v. DDAVP (p <0.02), times to peak levels (tmax) were shorter for i.v. DDAVP (p <0.001). There was no difference between the i.v. and s.c. routes for plasma DDAVP time curve (AUC) and half-life (ti/,), but there was much larger variability for pharmacokinetic parameters with i.v. than with s.c. DDAVP. Post-DDAVP VIII:C increased 3.4 ± 1.6 fold (i.v.) and 3.3 ±1.3 fold (s. c.) over baseline levels, with no significant correlation between peak VIII :C and DDAVP levels for either route of administration. These findings establish the s. c. route of DDAVP administration to be bioequivalent in effect to the i.v. route, albeit with less variability. At the DDAVP dosage used in this study and currently recommended for therapy, the VIII: C response is neither a function of the rate of absorption of the compound nor of the magnitude of its plasma concentration.
皮下注射去氨加压素（DDAVP）可缩短尿毒症患者的出血时间。
影响因子：
12.8
作者：
Viganò,GL;Mannucci,PM;Lattuada,A;Harris,A;Remuzzi,G
通讯作者：
Remuzzi,G